Pfizer Agrees to $250 Million Settlement Over Zantac Cancer Lawsuits

The pharmaceutical giant aims to resolve over 10,000 cases related to cancer risks from the discontinued heartburn medication.

Pfizer will pay between $200 million and $250 million to settle lawsuits over Zantac's cancer risks.
The settlement is intended to significantly reduce Pfizer's potential liability.
Zantac, once a top-selling drug, was pulled from the market in 2020 due to the presence of a probable carcinogen, NDMA.
The FDA found that NDMA levels in Zantac increased over time and with higher storage temperatures.
Other companies, including GSK and Sanofi, have also settled related lawsuits.